66 results
8-K
EX-1.1
PLSE
Pulse Biosciences, Inc.
15 Jul 24
Entry into a Material Definitive Agreement
7:10am
filed and no assessment in connection therewith has been made against the Company. The Company and its Subsidiaries have filed all other tax returns … to such returns or pursuant to any assessment received by the Company and its Subsidiaries, except for such taxes, if any, as are being contested in good faith
8-K
PLSE
Pulse Biosciences, Inc.
15 Jul 24
Entry into a Material Definitive Agreement
7:10am
to supplement investors’ and other readers’ understanding and assessment of the Company’s financial performance. The Company’s management uses
424B5
PLSE
Pulse Biosciences, Inc.
15 Jul 24
Prospectus supplement for primary offering
7:04am
up development, assessment, and review for premarket approval, 510(k) clearance, or De Novo marketing authorization. Breakthrough Devices must still … these non-GAAP financial measures in order to supplement investors’ and other readers’ understanding and assessment of our financial performance. Our
8-K
EX-99.1
PLSE
Pulse Biosciences, Inc.
8 Jul 24
Other Events
4:13pm
Program is intended to provide patients and health care providers with timely access to medical devices by speeding up development, assessment, and review
424B2
jyf1t5f
4 Jun 24
Prospectus for primary offering
4:05pm
SD
EX-1.01
xxlcbtn3sripqcaz bm
31 May 24
Conflict minerals disclosure
4:18pm
POS AM
8g1c6o
28 May 24
Prospectus update (post-effective amendment)
5:19pm
8-K
EX-99.1
xaoedk5r 848wjwz
7 May 24
Pulse Biosciences Reports Business Updates and First Quarter 2024 Financial Results
4:14pm
8-K
EX-99.1
evv3s1
28 Mar 24
Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2023 Financial Results
4:18pm